Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology

Standard of Care: First-Line Treatments by Subtype

At a Glance

Treatment for Marginal Zone Lymphoma (MZL) depends on your specific subtype. First-line care ranges from a 'watch and wait' approach for asymptomatic patients to antibiotics for gastric MALT, or targeted immunotherapies like rituximab for splenic MZL.

Treatment for Marginal Zone Lymphoma (MZL) is not “one size fits all.” Because MZL is often a slow-growing disease, the goal of treatment is to manage the lymphoma effectively while minimizing the impact on your daily life [1][2]. Depending on your specific subtype and symptoms, your initial “treatment” may be as simple as a course of antibiotics or a period of careful observation [3][4].

The Power of “Watch and Wait”

For many patients with Splenic or Nodal MZL who do not have symptoms, the standard of care is active surveillance, often called “watch and wait” [5][4].

  • What it is: Regular check-ups, blood tests, and physical exams to monitor the disease [4]. A typical ‘Watch and Wait’ visit usually involves a physical exam (feeling for enlarged lymph nodes or spleen) and a blood draw for a comprehensive metabolic panel and complete blood count (CBC).
  • Why it’s used: Clinical evidence shows that for asymptomatic patients, starting intensive treatment early doesn’t necessarily improve long-term survival but can introduce unnecessary side effects [5].
  • When it ends: Treatment begins only if you develop “B symptoms” (fevers, night sweats), significant pain from an enlarged spleen, or if your blood counts (like hemoglobin or platelets) begin to drop [6][5].

Gastric MALT: Treating the Cause

If you have gastric MALT lymphoma, the first step is often to treat the underlying trigger rather than the cancer itself [3].

  • Antibiotic Therapy: The vast majority of gastric MALT cases are caused by a bacterial infection called H. pylori [7]. Treating this infection with a combination of antibiotics and acid-blockers can lead to complete disappearance of the lymphoma in 70-90% of patients [3][8].
  • Even if Negative: Some doctors recommend antibiotic therapy even if tests for H. pylori come back negative, as it may still induce remission in some cases [9][10].
  • Radiation Therapy: If the lymphoma persists after antibiotics, low-dose involved-site radiation therapy (ISRT) is highly effective, with very high rates of local control and minimal side effects [11][12].

Splenic MZL (SMZL): Targeted Approaches

For patients with Splenic MZL who require treatment, the focus is often on reducing the size of the spleen and improving blood counts [5].

  • Rituximab Monotherapy: This is an immunotherapy that targets the CD20 protein on B-cells. It is often the preferred first-line treatment because it is highly effective and generally better tolerated than traditional chemotherapy [13][14].
  • Splenectomy: In some cases, surgically removing the spleen can provide a rapid improvement in symptoms and blood counts [15][5]. However, living without a spleen permanently compromises your immune system against certain bacteria, requiring special lifelong vaccination protocols to prevent severe infections.
  • Hepatitis C Treatment: If the lymphoma is associated with a Hepatitis C infection, treating the virus itself can sometimes cause the lymphoma to go into remission [16].

Advanced or Disseminated Disease

If the lymphoma is present in multiple sites or is causing significant symptoms, your doctor may recommend chemoimmunotherapy—a combination of the immunotherapy drug rituximab and chemotherapy [17].

  • Rituximab + Bendamustine (BR) or R-CHOP: These are some of the most common and effective regimens for advanced MZL [18][19].
  • Side Effects: While effective, these systemic treatments come with significant side effects, including an increased risk of infections, myelosuppression (lowered blood counts), fatigue, and nausea, requiring careful monitoring by your care team [20].

Non-Gastric MALT Lymphomas

For localized MALT lymphoma in other areas (like the eye, salivary glands, or skin), treatment is often localized [21]. Radiation therapy is frequently used as a primary treatment with excellent success [22]. If the disease is more widespread, systemic treatments like rituximab or rituximab-bendamustine are utilized [20].

Common questions in this guide

What does 'watch and wait' mean for MZL?
Watch and wait is an active surveillance approach involving regular physical exams and blood tests. Treatment only begins if you develop symptoms like fever, pain from an enlarged spleen, or dropping blood counts.
How do antibiotics treat gastric MALT lymphoma?
Most gastric MALT lymphomas are triggered by an H. pylori bacterial infection. Curing this underlying infection with antibiotics and acid-blockers can cause the lymphoma to disappear entirely in the majority of patients.
What is the standard treatment for splenic marginal zone lymphoma?
Treatment for splenic MZL focuses on reducing spleen size and improving blood counts. Rituximab immunotherapy is often the preferred first-line option, though surgical removal of the spleen or treating an underlying Hepatitis C infection may also be considered.
Will I need chemotherapy for marginal zone lymphoma?
Chemotherapy is typically reserved for advanced MZL that has spread to multiple sites or is causing significant symptoms. When used, it is often combined with immunotherapy drugs like rituximab to maximize effectiveness.
Can localized radiation be used for MZL?
Yes, low-dose radiation therapy is highly effective for localized non-gastric MALT lymphomas, such as those in the eye, salivary glands, or skin. It may also be used for gastric MALT if antibiotic therapy is unsuccessful.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific subtype, what are the first-line treatment options recommended by NCCN or ESMO guidelines?
  2. 2.If I am starting with antibiotic therapy for gastric MALT, what is the follow-up schedule to see if the lymphoma has regressed?
  3. 3.Am I a candidate for 'watch and wait,' and what specific symptoms or blood count changes would trigger the start of active treatment?
  4. 4.If we decide on rituximab, will it be given alone or in combination with chemotherapy like bendamustine?
  5. 5.Is localized radiation therapy an option for my disease, and what are the typical long-term side effects?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Mucosal-Associated Lymphoid Tissue Lymphoma in Southeast Asia: A 15-Year Retrospective Multicenter Study.

    Prayongratana K, Thamgrang T, Laoruangroj C, et al.

    Hematology reports 2025; (17(6)) doi:10.3390/hematolrep17060063.

    PMID: 41440761
  2. 2

    Prognostic outcome of extranodal marginal zone B-cell lymphoma: a nationwide cohort.

    Nam SY, Jo J

    Scientific reports 2025; doi:10.1038/s41598-025-32259-5.

    PMID: 41402369
  3. 3

    Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.

    Nakamura S, Hojo M

    Journal of clinical medicine 2022; (12(1)) doi:10.3390/jcm12010120.

    PMID: 36614921
  4. 4

    Splenic marginal zone lymphoma in Sweden 2000-2020: Increasing rituximab use and better survival in the elderly.

    Junlén HR, Sonnevi K, Lindén O, et al.

    EJHaem 2023; (4(3)):647-655 doi:10.1002/jha2.696.

    PMID: 37601869
  5. 5

    Risk-tailored treatment of splenic marginal zone lymphoma.

    Castelli R, Balzarotti M, Salvi E, et al.

    Anti-cancer drugs 2022; (33(1)):e36-e42 doi:10.1097/CAD.0000000000001165.

    PMID: 34407041
  6. 6

    Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.

    Bastidas-Mora G, Beà S, Navarro A, et al.

    British journal of haematology 2022; (196(1)):146-155 doi:10.1111/bjh.17815.

    PMID: 34519021
  7. 7

    Helicobacter pylori and Gastric Cancer.

    Kim J, Wang TC

    Gastrointestinal endoscopy clinics of North America 2021; (31(3)):451-465 doi:10.1016/j.giec.2021.03.003.

    PMID: 34053633
  8. 8

    Treatment of low-grade gastric MALT lymphoma using Helicobacter pylori eradication.

    Grgov S, Katić V, Krstić M, et al.

    Vojnosanitetski pregled 2015; (72(5)):431-6 doi:10.2298/vsp1505431g.

    PMID: 26165051
  9. 9

    Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma: a retrospective study in regions with a high prevalence of Helicobacter pylori infection.

    Kim JW, Yeom DH, Park SY, et al.

    BMC gastroenterology 2026; (26(1)).

    PMID: 41776408
  10. 10

    Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.

    Gong EJ, Ahn JY, Jung HY, et al.

    Gut and liver 2016; (10(5)):706-13 doi:10.5009/gnl15510.

    PMID: 27114423
  11. 11

    Long-term Clinical Efficacy of Radiotherapy for Patients with Stage I-II Gastric Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A Retrospective Multi-institutional Study.

    Jeong JU, Lee HC, Song JH, et al.

    Cancer research and treatment 2025; (57(2)):570-579 doi:10.4143/crt.2024.651.

    PMID: 39363583
  12. 12

    Reduced-dose Radiation Therapy for Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Multi-Institutional Prospective Study (KROG 16-18).

    Jeon SH, Chang JH, Kim IH, et al.

    International journal of radiation oncology, biology, physics 2025; (121(4)):1000-1005 doi:10.1016/j.ijrobp.2024.10.020.

    PMID: 39448038
  13. 13

    Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?

    Kalpadakis C, Pangalis GA, Angelopoulou MK, et al.

    Best practice & research. Clinical haematology 2018; (31(1)):65-72 doi:10.1016/j.beha.2017.10.011.

    PMID: 29452668
  14. 14

    Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.

    Scarfò L, Ferrari S, Frustaci AM, et al.

    Blood advances 2022; (6(18)):5356-5359 doi:10.1182/bloodadvances.2022007138.

    PMID: 35613463
  15. 15

    Splenic marginal zone lymphoma treated with laparoscopic splenectomy: A case report.

    Koyama R, Minagawa N, Maeda Y, et al.

    International journal of surgery case reports 2019; (65()):288-291 doi:10.1016/j.ijscr.2019.11.008.

    PMID: 31759300
  16. 16

    Lymphoma Remission by Interferon-Free HCV Eradication Without Chemotherapy.

    Lim LY, La D, Cserti-Gazdewich CM, Shah H

    ACG case reports journal 2015; (3(1)):69-70 doi:10.14309/crj.2015.104.

    PMID: 26504885
  17. 17

    Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis.

    Epperla N, Zhao Q, Moyo T, et al.

    Blood advances 2024; (8(3)):549-552 doi:10.1182/bloodadvances.2023011698.

    PMID: 38091577
  18. 18

    Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

    Iannitto E, Bellei M, Amorim S, et al.

    British journal of haematology 2018; (183(5)):755-765 doi:10.1111/bjh.15641.

    PMID: 30407629
  19. 19

    Extra-Nodal Marginal Zone Lymphoma (MZL) of MALT CD20+ of the Ocular Adnexa: Case Report.

    Rajabto W, Kevinsyah AP

    Maedica 2020; (15(1)):126-128 doi:10.26574/maedica.2020.15.1.126.

    PMID: 32419873
  20. 20

    A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

    Kiesewetter B, Willenbacher E, Willenbacher W, et al.

    Blood 2017; (129(3)):383-385 doi:10.1182/blood-2016-06-720599.

    PMID: 27879257
  21. 21

    Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

    Salar A, Domingo-Domenech E, Panizo C, et al.

    Blood 2017; (130(15)):1772-1774 doi:10.1182/blood-2017-07-795302.

    PMID: 28801448
  22. 22

    An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.

    Alderuccio JP, Arcaini L, Watkins MP, et al.

    Blood advances 2022; (6(7)):2035-2044 doi:10.1182/bloodadvances.2021006844.

    PMID: 35196377

This page provides educational information on first-line treatments for Marginal Zone Lymphoma. Always consult your hematologist or oncologist for personalized medical advice regarding your specific MZL subtype and care plan.

Get notified when new evidence is published on Marginal zone lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.